Cargando…
Risk of a first‐ever acute myocardial infarction and all‐cause mortality with sulphonylurea treatment: A population‐based cohort study
We investigated the association between the current use of individual sulphonylureas and the risk of a first‐ever acute myocardial infarction (AMI) and all‐cause mortality, in a population‐based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004‐2012)....
Autores principales: | van Dalem, Judith, Brouwers, Martijn C. G. J., Stehouwer, Coen D. A., Krings, André, Klungel, Olaf H., Driessen, Johanna H. M., de Vries, Frank, Burden, Andrea M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873381/ https://www.ncbi.nlm.nih.gov/pubmed/29171906 http://dx.doi.org/10.1111/dom.13168 |
Ejemplares similares
-
Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
por: van Dalem, Judith, et al.
Publicado: (2016) -
Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study
por: van Dalem, Judith, et al.
Publicado: (2021) -
Optimal utilisation of sulphonylureas in resource-constrained settings
por: Naidoo, Poobalan, et al.
Publicado: (2014) -
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
por: Chacra, A R, et al.
Publicado: (2009) -
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin‐naïve people with Type 2 diabetes: the DUAL IV trial
por: Rodbard, H. W., et al.
Publicado: (2016)